These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2667348)

  • 1. Practical considerations of recombinant human erythropoietin therapy.
    Paganini EP; Latham D; Abdulhadi M
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):19-25. PubMed ID: 2667348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of blood pressure changes during recombinant human erythropoietin therapy.
    Levin N
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for recombinant human erythropoietin therapy.
    Eschbach JW; Adamson JW
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):2-8. PubMed ID: 2667349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Who should receive recombinant human erythropoietin?
    Van Stone JC
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):3-7. PubMed ID: 2669084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients.
    Delano BG
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):14-8. PubMed ID: 2757025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to recombinant human erythropoietin therapy: a real clinical entity?
    Stivelman JC
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):8-11. PubMed ID: 2669085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron deficiency in patients with dialysis-associated anemia during erythropoietin replacement therapy: strategies for assessment and management.
    Van Wyck DB
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):21-4. PubMed ID: 2669082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
    Frenken LA; Verberckmoes R; Michielsen P; Koene RA
    Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life.
    Nissenson AR
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):25-31. PubMed ID: 2669083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iron management during recombinant human erythropoietin therapy.
    Van Wyck DB
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):9-13. PubMed ID: 2757026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of renal anemia by erythropoietin substitution. The effects on the cardiovascular system.
    Radermacher J; Koch KM
    Clin Nephrol; 1995 Nov; 44 Suppl 1():S56-60. PubMed ID: 8608665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of erythropoietin on the dialysis prescription.
    Van Wyck DB
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):71-5. PubMed ID: 1928083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
    Phair JP; Abels RI; McNeill MV; Sullivan DJ
    Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
    Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
    Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.
    Lundin AP
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):22-9. PubMed ID: 2648517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of patients' responses to epoetin alfa therapy.
    Krantz SB
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):15S-21S. PubMed ID: 2189124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
    Eschbach JW; Egrie JC; Downing MR; Browne JK; Adamson JW
    N Engl J Med; 1987 Jan; 316(2):73-8. PubMed ID: 3537801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.